Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Ixazomib	TA870 - Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
Ixekizumab (Taltz®)	TA422 - Ixekizumab for treating moderate to severe plaque psoriasis TA718 - Ixekizumab for treating axial spondyloarthritis
Lapatinib tablets	TA257 - Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2	Negative TA
Larotrectinib (Vitrakvi®)	TA630 - Larotrectinib for treating NTRK fusion-positive solid tumours
Lenalidomide capsules	TA171 - Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy TA322 - Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality TA586 - Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib TA587 - Lenalidomide plus dexamethasone for previously untreated multiple myeloma TA627 - Lenalidomide with rituximab for previously treated follicular lymphoma TA680 - Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma
Lenvatinib (Kisplyx®)	TA498 - Lenvatinib with everolimus for previously treated advanced renal cell carcinoma TA551 - Lenvatinib for untreated advanced hepatocellular carcinoma TA858 - Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma
Letrozole tablets	TA112 - Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer
Liraglutide (Saxenda®) (GLP1s should all be prescribed by brand name)	TA664 - Liraglutide for managing overweight and obesity	The use of Liraglutide for this indication is restricted to prescribing in secondary care by a specialist multidisciplinary Tier 3 weight management service with a commercial agreement in place. Prescribe by brand (Saxenda®) to avoid patients inadvertently receiving a different product licensed for type 2 diabetes.
Liraglutide (Victoza®) injection (GLP1s should all be prescribed by brand name)	NICE NG28: Type 2 diabetes in adults - management	THIS IS FOR DIABETES ONLY. Prescribe by brand (Victoza®) to avoid patients inadvertently receiving a different product licensed for obesity. 1.8 mg is non-formulary.
Lorlatinib (Lorviqua®)	TA628 - Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.